Statistical Design Flexibility Versus Optimism: The Example of KEYNOTE-604
Urania Dafni, ScD+more
In the era of targeted treatments and immunotherapies, it is relatively common to address multiple questions in a single phase III clinical trial. These questions often involve using more than […] Read more
Impactful Multidisciplinary Care Not Out of Reach in Community Settings
Leah LawrenceIn 2014 the IASLC, in collaboration with the American Thoracic Society and the European Respiratory Society, published a new classification of lung adenocarcinoma.1 The publication addressed new terminology and diagnostic […] Read more
Adjusting Occupational and Physical Therapy Services for Patients With Lung Cancer During the COVID-19 Pandemic
Pippa Labuc, BSc OT+more
The COVID-19 pandemic has had a significant impact on the role of therapy services for patients with a thoracic oncology diagnosis. Here we look at how two facilities, an occupational […] Read more
CT Findings of COVID-19 Pneumonia and Mimicking Diseases in Patients With Lung Cancer
Soon Ho Yoon, MD, PhD+more
The COVID-19 pandemic has caused more than 43.2 million cumulative cases and 1.16 million deaths, as of late October 2020. Approximately 1% of patients with COVID-19 have malignancy,1 and lung […] Read more
EGFR/ALK-Mutated NSCLC: Using Real-world Therapeutic Practices to Help Answer Real-world Therapeutic Questions
Shirish Gadgeel, MDILCN Editorial Group member Shirish M. Gadgeel, MD, is Chief of the Division of Hematology/Oncology at the Henry Ford Cancer Institute/Henry Ford Hospital. Dr. Gadgeel is currently working, in conjunction […] Read more
SBRT Versus Surgery in the COVID-19 Era: What Has Changed and What Hasn't?
Suresh Senan, MRCP, FRCR, PhDSurgery is considered the preferred treatment in patients with lung cancer who are fit to undergo the procedure. Stereotactic radiotherapy (SBRT) is guideline recommended for patients who are unfit for […] Read more
Increasing Understanding about the Role Biosimilar Agents in Everyday Practice: A Q&A with Dr. Gary Lyman (Part 1 of 2)
Gary Lyman, MD, MPHIn September 2017, the FDA approved bevacizumab-awwb for the treatment of NSCLC, with the same indications as the tradename agent. Although bevacizumab-awwb is the only biosimilar agent specific to lung […] Read more
December 18, 2020—The U.S. Food and Drug Administration (FDA) approved osimertinib as post-resection adjuvant therapy for patients with NSCLC and EGFR exon 19 deletions or exon 21 L858R mutations, as […] Read more
Leora Horn, MD, MSc, FRCPC, has joined AstraZeneca as the Global Head of Lung Cancer Strategy. Prior to joining AstraZeneca in September 2020, Dr. Horn was an Associate Professor of […] Read more
Associate Professor of Nursing at Yale University, Marianne J. Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP, added Fellow of the American Academy of Nursing (FAAN) to her impressive list […] Read more